Evidence map›Paper›PMID 42684504›Full record

ArticleNeurogenetics2026

High frequency of LRRK2 p.Gly2019Ser in Moroccan Parkinson's disease: RFLP as a reliable genotyping approach.

Sanae El Bardai, Ghita Aboulem, Youssef Ahmadi, Lamyae Errazouki, Najwa Bouhda, Imane Samri, Meriame Abbassi, Oussama Kettani, Fatima El Agy, Laila Chbani and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sanae El BardaiInterdisciplinary Laboratory of Health, Environment, and Health Techniques, High institute of nursing professions and health techniques, FES, Morocco. souina1974@gmail.com.ORCID http://orcid.org/0000-0001-5330-6968
Ghita AboulemDepartment of Neurology, University Hospital Center, FES, Morocco.
Youssef AhmadiDepartment of Medical Genetics and Oncogenetics, University Hospital Center, FES, Morocco.
Lamyae ErrazoukiDepartment of Medical Genetics and Oncogenetics, University Hospital Center, FES, Morocco.
Najwa BouhdaDepartment of Neurology, University Hospital Center, FES, Morocco.
Imane SamriDepartment of Medical Genetics and Oncogenetics, laboratory of Biomedical and Translational Research, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdallah University, FES, Morocco.
Meriame AbbassiInterdisciplinary Laboratory of Health, Environment, and Health Techniques, High institute of nursing professions and health techniques, FES, Morocco.
Oussama KettaniDepartment of Medical Genetics and Oncogenetics, University Hospital Center, FES, Morocco.
Fatima El AgyBiomedical and Translational Research Laboratory, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdallah University, FES, Morocco.
Laila ChbaniBiomedical and Translational Research Laboratory, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdallah University, FES, Morocco.
Ouafae MessouakDepartment of Neurology, University Hospital Center, FES, Morocco.
Laila BouguenouchDepartment of Medical Genetics and Oncogenetics, University Hospital Center, FES, Morocco.
Mohammed Faouzi BelahsenDepartment of Neurology, University Hospital Center, FES, Morocco.ORCID http://orcid.org/0000-0001-6061-4897
Karim OuldimDepartment of Medical Genetics and Oncogenetics, University Hospital Center, FES, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The LRRK2 c.6055G>A (p.Gly2019Ser) mutation represents one of the most frequent genetic causes of autosomal dominant Parkinson's disease (PD) worldwide. Morocco exhibits the highest documented global prevalence of this variant, with carrier rates approaching 38.8% among clinically diagnosed patients. This exceptional frequency positions the Moroccan population as a strategic reference point for genotype-driven PD research and therapeutic development. To capitalize on this epidemiological advantage while addressing infrastructural and financial constraints, we propose Restriction Fragment Length Polymorphism (RFLP) as a cost-effective and scalable genotyping alternative. RFLP allows precise single nucleotide polymorphism (SNP) detection via selective enzymatic digestion, and is seamlessly integrated into standard PCR workflows. By screening for the LRRK2 c.6055G>A mutation in a Moroccan cohort and performing comparative analysis with Sanger sequencing, we demonstrated the methodological robustness and strategic value of RFLP genotyping. This approach proved to be a reliable, reproducible, and cost-effective alternative, particularly suitable for routine screening in resource-limited settings.

Indexed as

Genotyping TechniquesLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseasePolymorphism, Restriction Fragment LengthGene FrequencyGenotypeHumansMoroccoMutationPolymorphism, Single NucleotideLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanLRRK2MoroccoParkinson’s diseasep.Gly2019SerRFLP

Identifiers

PMID42684504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.